Skip to main content
SpringerLink
Log in

New (Medical) Treatment for Thyroid Carcinoma

  • Reference work entry
  • First Online:
Thyroid Diseases

Part of the book series: Endocrinology ((ENDOCR))

Abstract

Treatment of locally advanced/metastatic thyroid cancer patients poses several challenges. The disease course can be rapidly progressive or can spontaneously remain stable over time. Periodic (3–12 months) imaging assessments are indicated. The tumor burden, location, and the pace of volume growth should be taken into account for treatment decision (Fig. 1). When small disease burden and no symptomatic/threatening lesion are present, the patient should be actively surveilled. In case of single/few threatening lesions, local treatment should be preferred. Large tumor burden and/or rapidly (<12 months) progressing disease are indicators for systemic treatments (Haugen et al. 2016). Approved (Tables 1 and 2) and investigational drugs (Table 3) for the treatment of thyroid cancer are presented in this chapter. Figure 2 shows all the cited kinase inhibitors and their targets in thyroid cancer cells and in endothelial cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 329.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akslen LA, Livolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol. 2000;31(4):439–42.

    Article  PubMed  CAS  Google Scholar 

  • Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab. 2007;92(12):4712–8.

    Article  PubMed  CAS  Google Scholar 

  • Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2016;101(7):2863–73.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014;24(5):918–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Brandhuber B, Haas J, Tuch B, Ebata K, Bouhana K, McFaddin E, et al. The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. Eur J Cancer. 2016;69:S144.

    Article  Google Scholar 

  • Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–28.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Brose MS, Troxel AB, Yarchoan M, Cohen AB, Harlacker K, Dyanick NA, et al. A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone. J Clin Oncol. 2015;33(15):6072.

    Google Scholar 

  • Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 2017;35(23):2692–9.

    Article  PubMed  Google Scholar 

  • Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF inhibitors: experience in thyroid cancer and general review of toxicity. Horm Cancer. 2015;6(1):21–36.

    Article  PubMed  CAS  Google Scholar 

  • Cabanillas ME, Busaidy NL, Zafereo M, Waguespack SG, Hu MI, Hofmann MC, et al. Neoadjuvant vemurafenib in patients with locally advanced papillary thyroid cancer (PTC). Eur Thyroid J. 2017;6(Suppl 1):38.

    Google Scholar 

  • Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.

    Article  CAS  Google Scholar 

  • Cao Y. Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis. Trends Mol Med. 2013;19(8):460–73.

    Article  PubMed  CAS  Google Scholar 

  • Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62:7284–90.

    PubMed  CAS  Google Scholar 

  • Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98(5):326–34.

    Article  PubMed  CAS  Google Scholar 

  • Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12):4700–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cheng L, Jin Y, Liu M, Ruan M, Chen L. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. Oncotarget. 2017;8(12):19843–54.

    Article  PubMed  PubMed Central  Google Scholar 

  • Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. 2016;76(13):3767–72.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cunha LL, Marcello MA, Rocha-Santos V, Ward LS. Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. Endocr-Relat Cancer. 2017;24(12):T261–81.

    Google Scholar 

  • Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, et al. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson cancer center off label experience. J Clin Endocrinol Metab. 2015;100(1):E77–81.

    Article  PubMed  CAS  Google Scholar 

  • Dadu R, Vilalabos PA, Para Cuentas ER, Rodriguez Canales J, Wistuba II, Zhou S, et al. Anaplastic thyroid cancer (ATC) is a hot immunogenic environment: immunoprofiling of a large cohort of ATC tumors. Thyroid. 2016;26(S1):OR-12.

    Google Scholar 

  • Dhar DK, Kubota H, Kotoh T, Tabara H, Watanabe R, Tachibana M, et al. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg. 1998;176(5):442–7.

    Article  PubMed  CAS  Google Scholar 

  • Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.

    Article  PubMed  CAS  Google Scholar 

  • Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, et al. BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur J Endocrinol. 2011;165(3):455–63.

    Article  PubMed  CAS  Google Scholar 

  • Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Fagin JA, Wells Jr SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893–901.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015;25(1):71–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, et al. New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci. 2015;16(3):6153–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013;19(15):4239–48.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017;5(6):469–81.

    Article  PubMed  CAS  Google Scholar 

  • Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112(2):296–305.

    Article  PubMed  CAS  Google Scholar 

  • Halilovic E, Solit DB. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol. 2008;8(4):419–26.

    Article  PubMed  CAS  Google Scholar 

  • Harris PJ, Bible KC. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011;20(10):1357–75.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4(3):175–80.

    Article  PubMed  CAS  Google Scholar 

  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy B, et al. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) with or without follicular elements. Clin Cancer Res. 2012;18(7):2056–65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017; 35(18_suppl):LBA2501-LBA.

    Article  Google Scholar 

  • Ishiwata T, Iino Y, Takei H, Oyama T, Morishita Y. Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep. 1998;5(6):1343–8.

    PubMed  CAS  Google Scholar 

  • Iyer P, Dadu R, Busaidy N, Ferrarotto R, Gule-Monroe M, Lu C, et al. Harvesting high-hanging fruit: Targeted therapy for BRAF mutant (BRAFm) and BRAF wild-type (BRAFwt) anaplastic thyroid cancer (ATC). Thyroid. 2016;26(Suppl 1):A64–A5.

    Google Scholar 

  • Jaber T, Waguespack SG, Cabanillas ME, Vu T, Santos EB, Dadu R, et al. Efficacy of targeted therapy in resensitization to radioactive iodine (RAI) in advanced thyroid cancer: The MD Anderson experience. Endocr Rev. 2017;38(3 Supplement):OR39–6.

    Google Scholar 

  • Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88(4):271–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 2006;116(6):1561–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4871 patients. Clin Cancer Res. 2017;23(8):1988–97.

    Article  PubMed  CAS  Google Scholar 

  • Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66.

    Article  PubMed  CAS  Google Scholar 

  • Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013;23(10):1277–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):656–8.

    Article  PubMed  CAS  Google Scholar 

  • Kollipara R, Schneider B, Radovich M, Babu S, Kiel PJ. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist. 2017;22(10):1149–51.

    Article  PubMed  PubMed Central  Google Scholar 

  • Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer. 2014;120(13):1920–31.

    Article  PubMed  CAS  Google Scholar 

  • Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007;67(2):593–9.

    Article  PubMed  CAS  Google Scholar 

  • Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, et al. Antiangiogenic tyrosine kinase inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer. J Clin Endocrinol Metab. 2016;101(7):2733–41.

    Article  PubMed  CAS  Google Scholar 

  • Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–66.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001;129:552–8.

    Article  PubMed  CAS  Google Scholar 

  • Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, et al. Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations. Clin Cancer Res. 2017;23(12):2981–90.

    Article  PubMed  CAS  Google Scholar 

  • Lim SM, Chang H, Yoon MJ, Hong YK, Kim H, Chung WY, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24(12):3089–94.

    Article  PubMed  CAS  Google Scholar 

  • Lim AM, Taylor GR, Fellowes A, Cameron L, Lee B, Hicks RJ, et al. BRAF inhibition in BRAFV600E-positive anaplastic thyroid carcinoma. J Natl Compr Canc Netw. 2016;14(3):249–54.

    Article  PubMed  Google Scholar 

  • Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr-Relat Cancer. 2016;23(3):R143–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lorch JH, Busaidy N, Ruan DT, Janne PA, Limaye SA, Wirth LJ, et al. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). J Clin Oncol. 2013;31(15):6023.

    Google Scholar 

  • Mancikova V, Inglada-Perez L, Curras-Freixes M, de Cubas AA, Gomez A, Leton R, et al. VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma. Thyroid. 2014;24(8):1251–5.

    Article  PubMed  CAS  Google Scholar 

  • Marotta V, Sciammarella C, Vitale M, Colao A, Faggiano A. The evolving field of kinase inhibitors in thyroid cancer. Crit Rev Oncol Hematol. 2015;93(1):60–73.

    Article  PubMed  CAS  Google Scholar 

  • Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664–71.

    Article  PubMed  CAS  Google Scholar 

  • Mehnert JM, Varga A, Brose M, Aggarwal RR, Lin C-C, Prawira A, et al. Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J Clin Oncol. 2016;34(15_suppl):6091.

    Article  Google Scholar 

  • Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Discov. 2013;3(5):520–33.

    Google Scholar 

  • Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103.

    Article  PubMed  CAS  Google Scholar 

  • Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359–71.

    Article  PubMed  CAS  Google Scholar 

  • Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res. 2006;12(6):1785–93.

    Article  PubMed  CAS  Google Scholar 

  • Prager GW, Koperek O, Mayerhoefer ME, Muellauer L, Wrba F, Niederle B, et al. Sustained response to vemurafenib in a BRAFV600E-mutated anaplastic thyroid carcinoma patient. Thyroid. 2016;26(10):1515–6.

    Article  PubMed  CAS  Google Scholar 

  • Rahal R, Evans EK, Hu W, Maynard M, Fleming P, DiPietro L, et al. The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors. Cancer Res. 2016;76(14 Supplement):2641.

    Article  Google Scholar 

  • Rheault TR, Stellwagen JC, Adjabeng GM, Hornberger KR, Petrov KG, Waterson AG, et al. Discovery of dabrafenib: a selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors. ACS Med Chem Lett. 2013;4(3):358–62.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885–93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Rodriguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer. 2010;17(1):7–16.

    Article  PubMed  CAS  Google Scholar 

  • Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21(5):1028–35.

    Google Scholar 

  • Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321:20–8.

    Article  PubMed  CAS  Google Scholar 

  • Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res. 2008;6(5):751–9.

    Article  PubMed  CAS  Google Scholar 

  • Schlumberger M, Jarzab B, Elisei R, Siena S, Bastholt L. de la Fouchardiere C. Phase III randomized, double-blinded, placebo-controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)-exploratory analyses of patient-reported outcomes. Thyroid. 2013;23(Suppl. 1):A-49.

    Google Scholar 

  • Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.

    Article  PubMed  CAS  Google Scholar 

  • Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJM, Gelderblom H, et al. Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial. Int J Endocrinol. 2015;2015:348124.

    Article  CAS  Google Scholar 

  • Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJM, Gelderblom H, et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial. J Clin Endocr Metab. 2017;102(2):698–707.

    PubMed  Google Scholar 

  • Shah MH, Wei L, Wirth LJ, Daniels GA, Souza JAD, Timmers CD, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol. 2017;35(15_suppl):6022.

    Article  Google Scholar 

  • Sharma P, Allison JP. The future of immune checkpoint therapy. Science (New York, NY). 2015;348(6230):56–61.

    Article  CAS  Google Scholar 

  • Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22:464–8.

    Article  CAS  Google Scholar 

  • Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol. 2013;49(7):707–10.

    Article  PubMed  CAS  Google Scholar 

  • Sherman EJ, Ho AL, Fury MG, Baxi SS, Dunn L, Lee JS, et al. Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on phase II study. J Clin Oncol. 2015;33(15):6069.

    Google Scholar 

  • Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schoffski P, et al. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016;122(24):3856–64.

    Article  PubMed  CAS  Google Scholar 

  • Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. 2017;123(21):4114–21.

    Article  PubMed  CAS  Google Scholar 

  • Soh EY, Clark OH. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin N Amer. 1996;25:115–39.

    Article  CAS  Google Scholar 

  • Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery. 2000;128(6):1059–65; discussion 65–6.

    Article  PubMed  CAS  Google Scholar 

  • Spitzweg C, Bible KC, Hofbauer LC, Morris JC. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014;2(10):830–42.

    Article  PubMed  CAS  Google Scholar 

  • St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146(3):1145–53.

    Article  PubMed  CAS  Google Scholar 

  • Subbiah V, Roszik J. Towards precision oncology in RET-aberrant cancers. Cell Cycle. 2017;16(9):813–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria J-C, et al. Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC). J Clin Oncol. 2017;35(15_suppl):6023.

    Article  Google Scholar 

  • Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: final analysis results. J Clin Oncol. 2016;34:6088.

    Google Scholar 

  • Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23(6):1388–96.

    Article  CAS  PubMed  Google Scholar 

  • Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(12):1671–80; quiz 80.

    Article  PubMed  Google Scholar 

  • Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, et al. RET mutation and increased angiogenesis in medullary thyroid carcinomas. Endocr-Relat Cancer. 2016;23(8):665–76.

    Article  PubMed  CAS  Google Scholar 

  • Verschraegen CF, Rehman H, Pulluri B, DeKay J, Barry M, Folefac E, et al. When clinical trial participation is not an option in the era of personalized medicine: the case of two patients. Oncology. 2017;92(1):55–60.

    Article  PubMed  Google Scholar 

  • Vieira JM, Santos SCR, Espadinha C, Correia I, Vag T, Casalou C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol. 2005;153(5):701–9.

    Article  PubMed  CAS  Google Scholar 

  • Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645–55.

    PubMed  CAS  Google Scholar 

  • Wells Jr SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–41.

    Article  PubMed  CAS  Google Scholar 

  • White PS, Pudusseri A, Lee SL, Eton O. Intermittent dosing of dabrafenib and trametinib in metastatic BRAFV600E mutated papillary thyroid cancer: two case reports. Thyroid. 2017;27(9):1201–5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.

    Article  PubMed  CAS  Google Scholar 

  • Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33(1):42–50.

    Article  PubMed  Google Scholar 

  • Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308.

    Article  PubMed  CAS  Google Scholar 

  • Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576–83.

    Article  PubMed  CAS  Google Scholar 

  • Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11(22):8063–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Medical Specialties, University of Rome Sapienza, Rome, Italy

    Sebastiano Filetti

  2. Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Steven I. Sherman

Authors
  1. Sebastiano Filetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven I. Sherman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastiano Filetti .

Editor information

Editors and Affiliations

  1. Department of Endocrinology, University of Pisa, Pisa, Italy

    Paolo Vitti

  2. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

    Laszlo Hegedüs

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Filetti, S., Sherman, S.I. (2018). New (Medical) Treatment for Thyroid Carcinoma. In: Vitti, P., Hegedüs, L. (eds) Thyroid Diseases. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-45013-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45013-1_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45012-4

  • Online ISBN: 978-3-319-45013-1

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation